http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020168760-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ba759486f7b206f2eef2b9c8bfa88c4c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-125 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-105 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-125 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 |
| filingDate | 2019-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3337d87cb33316b5109bf13f9bfb3dd4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31da11608b0fae689ab9b62885b17e6e |
| publicationDate | 2020-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020168760-A1 |
| titleOfInvention | Use of albiflorin in preparation of drugs for rapidly treating depression |
| abstract | Provided is use of albiflorin or pharmaceutically acceptable salts thereof, or extracts containing albiflorin or pharmaceutically acceptable salts thereof in preparation of drugs, foods, healthcare products, food additives or nutritional supplements for rapidly treating depression by inhibiting an NMDA receptor. Also provided is use of albiflorin or pharmaceutically acceptable salts thereof, or extracts containing albiflorin or pharmaceutically acceptable salts thereof in preparation of NMDA receptor inhibitors. In addition, also provided is a method for rapidly treating depression by inhibiting an NMDA receptor. Compared with various rapid-acting anti-depression drugs under development such as ketamine, NMDA receptor inhibitors, albiflorin and pharmaceutically acceptable salts thereof are safer, do not yield any mental side effect such as dissociation and hallucination, and likewise do not have the hidden trouble of addiction. |
| priorityDate | 2019-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 48.